-
Kenya's economy faces climate change risks: World Bank
-
BP profits slide awaiting new CEO
-
Trump tariffs hurt French wine and spirits exports
-
OpenAI starts testing ads in ChatGPT
-
Back to black: Philips posts first annual profit since 2021
-
Man arrested in Thailand for smuggling rhino horn inside meat
-
'Family and intimacy under pressure' at Berlin film festival
-
Asian markets extend gains as Tokyo enjoys another record day
-
Unions rip American Airlines CEO on performance
-
Jury told that Meta, Google 'engineered addiction' at landmark US trial
-
Three missing employees of Canadian miner found dead in Mexico
-
Meta, Google face jury in landmark US addiction trial
-
Epstein accomplice Maxwell seeks Trump clemency before testimony
-
Some striking NY nurses reach deal with employers
-
Emergency measures kick in as Cuban fuel supplies dwindle under US pressure
-
EU chief backs Made-in-Europe push for 'strategic' sectors
-
AI chatbots give bad health advice, research finds
-
Iran steps up arrests while remaining positive on US talks
-
Bank of France governor Francois Villeroy de Galhau to step down in June
-
EU warns Meta it must open up WhatsApp to rival AI chatbots
-
Japan restarts world's biggest nuclear plant again
-
Japan's Takaichi may struggle to soothe voters and markets
-
'Want to go home': Indonesian crew abandoned off Africa demand wages
-
Arguments to begin in key US social media addiction trial
-
Trump says China's Xi to visit US 'toward the end of the year'
-
'Send Help' repeats as N.America box office champ
-
US astronaut to take her 3-year-old's cuddly rabbit into space
-
UK foreign office to review pay-off to Epstein-linked US envoy
-
Storm-battered Portugal votes in presidential election run-off
-
French police arrest five over crypto-linked magistrate kidnapping
-
De Beers sale drags in diamond doldrums
-
What's at stake for Indian agriculture in Trump's trade deal?
-
Pakistan's capital picks concrete over trees, angering residents
-
Neglected killer: kala-azar disease surges in Kenya
-
Chile's climate summit chief to lead plastic pollution treaty talks
-
Spain, Portugal face fresh storms, torrential rain
-
Opinions of Zuckerberg hang over social media addiction trial jury selection
-
Crypto firm accidentally sends $40 bn in bitcoin to users
-
Dow surges above 50,000 for first time as US stocks regain mojo
-
Danone expands recall of infant formula batches in Europe
-
EU nations back chemical recycling for plastic bottles
-
Why bitcoin is losing its luster after stratospheric rise
-
Stocks rebound though tech stocks still suffer
-
Digital euro delay could leave Europe vulnerable, ECB warns
-
German exports to US plunge as tariffs exact heavy cost
-
Stellantis takes massive hit for 'overestimation' of EV shift
-
'Mona's Eyes': how an obscure French art historian swept the globe
-
In Dakar fishing village, surfing entices girls back to school
-
Russian pensioners turn to soup kitchen as war economy stutters
-
As Estonia schools phase out Russian, many families struggle
The scientist rewriting DNA, and the future of medicine
A revolution is underway in gene editing -- and at its forefront is David Liu, an American molecular biologist whose pioneering work is rewriting the building blocks of life with unprecedented precision.
A professor at the Broad Institute of MIT and Harvard, Liu was awarded a Breakthrough Prize in Life Sciences on Saturday for developing two transformative technologies: one already improving the lives of patients with severe genetic diseases, the other poised to reshape medicine in the years ahead.
He spoke with AFP ahead of the Los Angeles ceremony for the prestigious Silicon Valley-founded award.
He will receive $3 million for his work on "base editing" and "prime editing," and plans to donate most of it to support his charitable foundation.
"The ability to change a DNA sequence of our choosing into a new sequence of our choosing is a fundamentally very powerful capability," the 51-year-old said, foreseeing uses not just in human medicine but areas like developing more nutritious or disease-resistant crops.
- Correcting the code -
DNA is made up of four chemical "letters" -- the nucleotide bases A, G, T and C. Mutations in this sequence cause thousands of human diseases, yet until recently, gene editing could only fix a limited number of them.
Even CRISPR-Cas9, the groundbreaking technology that earned a Nobel Prize in 2020, has major limitations.
It cuts both strands of the DNA helix, making it most useful to disrupt rather than correct genes, while the process can introduce new errors.
"Being able to use genome editing to treat genetic diseases requires, in most cases, ways to correct a DNA misspelling, not simply to disrupt a gene," Liu said.
That insight led his lab to develop base editing, which uses the Cas9 protein -- disabled so it can no longer cut both DNA strands -- to find a target DNA sequence and another enzyme to convert one letter to another -- for example, C to T or G to A.
Reversing the change -- from T to C or A to G -- was tougher. Liu's team overcame the challenge by engineering entirely new enzymes.
These base editors can now correct about 30 percent of the mutations that cause genetic diseases. The technology is already in at least 14 clinical trials.
In one of them, Beam Therapeutics -- which Liu co-founded -- announced it had treated patients of AATD, a rare genetic disorder affecting the lungs and liver, with a single drug infusion.
While traditional gene therapies often disrupt faulty genes or work around them, base editing repairs the mutation itself.
"This was the first time that humans have corrected a mutation that causes a genetic disease in a patient," Liu said.
- Cystic fibrosis hope -
Base editing, quickly dubbed "CRISPR 2.0," can't fix every mutation.
About 70 percent of the roughly 100,000 known disease-causing mutations remain out of its reach, including those caused by missing or extra letters.
To expand the toolkit, Liu's lab introduced prime editing in 2019 -- a method capable of replacing entire sections of faulty DNA with corrected sequences.
If CRISPR is like scissors that cut DNA, and base editors are like using a pencil to correct individual letters, then prime editing is the equivalent of a word processor's "find and replace" function.
Creating this tool required a series of breakthroughs Liu's team describes as "small miracles." The result is, he said, "the most versatile way we know of to edit the human genome."
Among the targets Liu and his team have already pursued with prime editing: cystic fibrosis, a common genetic disease usually caused by three missing DNA letters that causes thick mucus buildup in the lungs and digestive system.
Liu's lab has made much of its work freely accessible, sharing DNA blueprints through a nonprofit library used by tens of thousands of labs worldwide.
"The science we create -- which is ultimately funded by society, through governments and donors -- ultimately goes back to benefit society."
This year's Breakthrough Prize awards come at a fraught moment for US science, as President Donald Trump's government strips funding for institutions like the National Institutes of Health (NIH).
"The NIH is a treasure, not just for this country but for the world," said Liu. "Trying to dismantle the heart of what supports science in this country is like burning your seed corn."
Y.Uduike--CPN